drugset / Trial / NCT00290732

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

NCT00290732 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy in different ways, such as into the breast ducts, may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given before mastectomy in treating women with invasive breast cancer.

Timeline

Start
2005-11
Primary completion
2011-05
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 1 mg Other
Subject Doxorubicin Other / unclassified 2 mg Other
Subject Doxorubicin Other / unclassified 5 mg Other
Subject Doxorubicin Other / unclassified 10 mg Other

Indications